Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
45.81
-0.37 (-0.80%)
At close: Jun 5, 2026, 4:00 PM EDT
46.72
+0.91 (1.99%)
After-hours: Jun 5, 2026, 7:53 PM EDT
Travere Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 78.36 | 93.04 | 58.54 | 58.18 | 61.69 | 165.75 |
Short-Term Investments | 186.31 | 229.76 | 312.17 | 508.68 | 388.56 | 387.13 |
Cash & Short-Term Investments | 264.68 | 322.8 | 370.7 | 566.85 | 450.25 | 552.88 |
Cash Growth | -17.86% | -12.92% | -34.60% | 25.90% | -18.56% | 52.90% |
Accounts Receivable | 87.3 | 80.13 | 27.12 | 21.18 | 16.65 | 15.91 |
Total Trade Receivables | 87.3 | 80.13 | 27.12 | 21.18 | 16.65 | 15.91 |
Inventory | 30.7 | 30.28 | 35.66 | 31.49 | 4.52 | 7.31 |
Other Current Assets | 34.35 | 28.76 | 12.69 | 19.34 | 15.02 | 6.72 |
Total Current Assets | 392.68 | 437.57 | 416.7 | 616.78 | 486.44 | 582.83 |
Net Property, Plant & Equipment | 13.3 | 14.6 | 19.63 | 25.54 | 30.05 | 34.3 |
Other Intangible Assets | 110.04 | 113.87 | 103.97 | 104.44 | 97.07 | 148.44 |
Other Long-Term Assets | 8.48 | 8.88 | 18.16 | 10.66 | 59.03 | 11.07 |
Total Assets | 555.19 | 605.19 | 594.13 | 788.91 | 672.59 | 776.63 |
Accounts Payable | 12.91 | 24.8 | 23.53 | 41.68 | 17.29 | 15.14 |
Accrued Expenses | 104.41 | 126.04 | 86.03 | 118.99 | 95.74 | 75.18 |
Current Portion of Long-Term Debt | - | - | 68.68 | - | - | - |
Current Portion of Leases | 6.02 | 5.88 | 5.41 | 4.91 | 4.43 | 3.91 |
Unearned Revenue | - | - | - | 7.1 | 11.98 | 16.27 |
Other Current Liabilities | 2.1 | 3.19 | 17.11 | 5.24 | 12.72 | 13.59 |
Total Current Liabilities | 125.44 | 159.9 | 200.75 | 177.91 | 142.16 | 124.09 |
Long-Term Debt | 312.08 | 311.72 | 310.31 | 377.26 | 375.55 | 226.58 |
Long-Term Leases | 9.57 | 11.13 | 17.19 | 22.61 | 27.51 | 31.5 |
Other Long-Term Liabilities | 9.38 | 7.6 | 6.8 | 10.32 | 84.52 | 92.36 |
Total Long-Term Liabilities | 331.02 | 330.46 | 334.3 | 410.2 | 487.57 | 350.43 |
Total Liabilities | 456.46 | 490.36 | 535.05 | 588.1 | 629.73 | 474.52 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-in Capital | 1,610 | 1,589 | 1,506 | 1,328 | 1,060 | 1,069 |
Accumulated Other Comprehensive Income | -1.06 | -1.19 | -0.08 | -1.46 | -2.91 | -0.56 |
Retained Earnings | -1,510 | -1,473 | -1,447 | -1,126 | -1,014 | -765.97 |
Shareholders' Equity | 98.73 | 114.83 | 59.08 | 200.81 | 42.85 | 302.11 |
Total Liabilities & Equity | 555.19 | 605.19 | 594.13 | 788.91 | 672.59 | 776.63 |
Total Debt | 327.66 | 328.73 | 401.58 | 404.78 | 407.49 | 261.99 |
Net Cash (Debt) | -62.99 | -5.94 | -30.88 | 162.07 | 42.76 | 290.9 |
Net Cash Growth | - | - | - | 279.04% | -85.30% | 147.45% |
Net Cash Per Share | -0.67 | -0.07 | -0.39 | 2.18 | 0.67 | 4.86 |
Book Value | 98.73 | 114.83 | 59.08 | 200.81 | 42.85 | 302.11 |
Book Value Per Share | 1.06 | 1.29 | 0.75 | 2.70 | 0.67 | 5.05 |
Tangible Book Value | -11.31 | 0.96 | -44.9 | 96.37 | -54.22 | 153.68 |
Tangible Book Value Per Share | -0.12 | 0.01 | -0.57 | 1.30 | -0.85 | 2.57 |